AB Science presents annual financial results as of 31 December 2025, focusing on operating loss reduction and key clinical developments like Phase 3 of masitinib in ALS and Phase 1 of AB8939 in AML ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results